Today's Datapoint

36,000... was the price Pharmasset, Inc. was planning to charge for a three-month supply of the hepatitis C drug Sovaldi before the firm was acquired by Gilead Sciences Inc., which charges $84,000 for a three-month treatment cycle, according to information acquired by the Senate Finance Committee.